Phase I study of Androgen deprivation therapy in combination with anti-PD-1 in patients pre- treated with anti-PD-1.
Caroline RobertCeleste LebbèThierry LesimpleEija LundströmValérie NicolasBruno GavilletPhilippa CromptonBaryour BaroudijianÉmilie RoutierFerdy J LejeunePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
This combination was well tolerated. Disease control in 42.8% (RECIST) and 50% (iRECIST).Thymus rejuvenation was limited.